vimarsana.com
Home
Live Updates
GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 : comparemela.com
GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021
/PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based...
Related Keywords
Switzerland ,
Jeff Miller ,
David Castaneda ,
Beverly Hills ,
Gregory Berk ,
Exchange Commission ,
University Of Minnesota ,
Gt Biopharma Inc ,
European Society For Medical Oncology ,
Oncology Io Congress ,
European Society ,
Medical Oncology ,
Chief Medical Officer ,
Interim Chief Executive ,
Acute Myelogenous Leukemia ,
Myelodysplastic Syndrome ,
Engagers Display Robust ,
Poster Display Title ,
Tri Specific Killer Engager ,
Annual Report ,
Quarterly Report ,
Securities Act ,
Gt Biopharma ,
Nc ,
comparemela.com © 2020. All Rights Reserved.